Combination mTOR and IGF-1R inhibition: Phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors

Clinical Cancer Research

Volumn 17, Issue 4, 2011, Pages 871-879

  Quek, Richard ^a   Wang, Qian ^a   Morgan, Jeffrey A ^a   Shapiro, Geoffrey I ^a   Butrynski, James E ^a   Ramaiya, Nikhil ^a   Huftalen, Tarsha ^a   Jederlinic, Nicole ^a   Manola, Judith ^a   Wagner, Andrew J ^a   Demetri, George D ^a   George, Suzanne ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; FIGITUMUMAB; MAMMALIAN TARGET OF RAPAMYCIN; SOMATOMEDIN C RECEPTOR;

ACNE; ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CHONDROSARCOMA; CHORDOMA; CLINICAL ARTICLE; COLON CANCER; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DUODENUM ULCER; DYSPHAGIA; ENTERITIS; EPISTAXIS; ESOPHAGITIS; EWING SARCOMA; EYE DISEASE; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEIOMYOSARCOMA; LIMB PAIN; LYMPHOCYTOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; OSTEOSARCOMA; PERIVASCULAR EPITHELIOID CELL TUMOR; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; RECOMMENDED DRUG DOSE; SARCOMA; SIDE EFFECT; SOLID TUMOR; SPINDLE CELL SARCOMA; STOMACH PAIN; STOMATITIS; TASTE DISORDER; THROMBOCYTE COUNT; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; WOUND COMPLICATION; XEROSTOMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RECEPTOR, IGF TYPE 1; SARCOMA; SIROLIMUS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 79951816312     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2621     Document Type: Article

References (34)

1. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48.
2. Zha J, Lackner MR. Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin Cancer Res 2010;16:2512-7.
3. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18. (Pubitemid 38868620)
4. Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A, Baserga R. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci U S A 1993;90:11217-21. (Pubitemid 23354400)
5. Sell C, Dumenil G, Deveaud C, Coppola D, DeAngelis T. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994;14:3604-12. (Pubitemid 24160768)
6. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, et al. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994;54: 2218-22. (Pubitemid 24138698)
7. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 1994;54:4848-50. (Pubitemid 24289413)
8. Tolcher AW, Sarantopoulos J, Patnaik A, Lin CC, Rodon Papadopoulos J. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009;27:5800-7.
9. Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, et al. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11:129-35.
10. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, et al. A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clin Cancer Res. 2010;16:2458-65.
11. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5:671-88. (Pubitemid 44151605)
12. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
13. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005;65:7052-8. (Pubitemid 41161231)
14. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8. (Pubitemid 43259931)
15. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with RAD001: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008;26:1603-10.
16. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willets L, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008;111:379-82.
17. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res 2009;69:7662-71.
18. O'Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26:1588-95.
19. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13:5834-40. (Pubitemid 47583908)
20. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. RECORD-1 Study Group. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
21. Haluska P, Worden F, Olmos D, Yin D, Schteingart D, Batzel GN, et al. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother Pharmacol 2010; 65:765-73.
22. Di Cosimo S, Bendell JC, Cervantes-Ruiperez A, Roda D, Prudkin L, Stein MN, et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. ASCO Meeting Abstr 201028:3008
23. Naing A, LoRusso P, Gupta S, Rohren E, Chen Benjamin HX, et al. dual inhibition of IGFR and mTOR pathways. ASCO Meeting Abstr 201028: 3007
24. Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008;26: 3196-203.
25. Pappo AS, Patel S, Crowley J, Reinke DK, Staddon AP, Kuenkele K, et al. and Sarcoma Alliance for Research through Collaboration. Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study. ASCO Meeting Abstr 201028:10000.
26. Tap WD, Demetri GD, Barnette P, Desai J, Kavan P, Tozer R, et al. AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results. ASCO Meeting Abstr 201028:10001
27. Carden CP, Frentzas S, Langham M, Casamayor I, Stephens AW, Poondru S, et al. Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors. ASCO Meeting Abstr 200927:3544
28. Chawla SP, Tolcher AW, Staddon AP, Schuetze S, D'Amato GZ, Blay JY, et al. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial. ASCO Meeting Abstr 200725:10076
29. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 2009;27: 3154-60.
30. Stacchiotti S, Negri T, Palassini E, Conca E, Gronchi A, Morosi C, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther 2010;9: 1286-97.
31. Le Roith D. Tumor induced hypoglycemia [editorial;comment]. N Engl J Med 1999;341:757-8.
32. Le Roith D. Seminars in medicine of the Beth Isreal Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 1997;336: 633-40.
33. Li Y, Chang Q, Rubin BR, Fletcher CDM, Morgan TW, Mentzer SJ, et al. Insulin receptor activation in solitary fibrous tumor. J Pathol 2007;211;550-4. (Pubitemid 46502431)
34. Kalebi AY, Hale MJ, Wong ML, Hoffman T, Murray J. Surgically cured hypoglycemia secondary to pleural solitary fibrous tumour: case report and update on the Doege-Potter syndrome. J Cardiothoracic Surg 2009;4:45.